Share on LinkedInShare on LinkedIn

ARTICLE · 04 SEPTEMBER 2023

DOJ Obtains First Divestitures In A Criminal Antitrust Case

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The U.S. Department of Justice Antitrust Division ("DOJ") recently resolved a criminal case with Teva Pharmaceuticals and Glenmark Pharmaceuticals via deferred prosecution agreements ("DPAs")...

United StatesAntitrust/Competition Law

Seeking divestitures in a criminal case sets precedent for DOJ and is consistent with the Administration's mantra of "every tool in the kit" approach to aggressive antitrust enforcement.

The U.S. Department of Justice Antitrust Division ("DOJ") recently resolved a criminal case with Teva Pharmaceuticals and Glenmark Pharmaceuticals via deferred prosecution agreements ("DPAs"), which include a novel remedy for a criminal antitrust case: divestiture. The "usual" penalty for a corporation for a criminal antitrust violation is a fine and possibly probation.

DOJ indicted Glenmark in June 2020, and Teva in August 2020, for their participation in alleged conspiracies to allocate customers and rig bids for, and fix prices of, generic drugs sold in the United States. By entering the DPAs, Teva and Glenmark avoided debarment from participating in U.S. federal health care programs.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from